GSK and Stevenage Bioscience Catalyst are delighted to host this summit to explore the UK advantage in Cell and Gene Therapy. How can joining up science and value in cell and gene therapy deliver global health impact? The summit will explore the journey from science to patients and what value means for different people and organisations.
BioBeat19: Accelerating Cell and Gene Therapy
13.00 - 13.20 Registration
13.20 - 13.30 Welcome
Miranda Weston-Smith, BioBeat, Sally Ann Forsyth, Stevenage Bioscience Catalyst, Victoria Higgins, GSK
13.30 - 14.00 Keynote address: Emma Walmsley, CEO, GSK - C> at GSK: Innovation and Value Creation
14.00-15.00 - Panel 1: Leveraging Science
This panel lives the translational journey from scientific innovation to scale up of C> and asks: where are the biggest opportunities?
Soraya Bekkali, Gyroscope, Tamsin Berry, Office of Life Sciences, Aisha Hasn, GSK, Emma Moris, UCL Institute of Immunity and Transplantation (Chair), Sophie Papa, King's College London
15.30-16.30 - Panel 2: Optimising Value
This panel unwraps the drivers for value in C>, from commercial return to impact on health, and asks: how best to balance needs?
Karen Hodgkin, CellMedica (Chair), Jeanette Kusel, NICE, Anna Outhwaite, Cell and Gene Therapy Catapult, Tara Raveendran, Shore Capital, Jane Whitrow, Freeline Therapeutics
16.30 - 16.35 Close and Thanks
16.35-18.00 Refreshments and Networking
This half day event is for scientists, investors and entrepreneurs. Leading women will discuss opportunities and catalyse ideas with the audience. Open to all.
Please register at www.biobeat19.org.
Miranda helps early stage biomedical businesses to attract investment and develop their business strategy. Miranda founded and runs BioBeat, a programme to inspire the next wave of bioentrepreneurs and business leaders